MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beukers, M. W.
Right arrow Articles by Ijzerman, A. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beukers, M. W.
Right arrow Articles by Ijzerman, A. P.

Vol. 58, Issue 6, 1349-1356, December 2000

Why Are A2B Receptors Low-Affinity Adenosine Receptors? Mutation of Asn273 to Tyr Increases Affinity of Human A2B Receptor for 2-(1-Hexynyl)adenosine

Margot W. Beukers, Hans den Dulk, Erica W. van Tilburg, Jaap Brouwer, and Adriaan P. Ijzerman

Division of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research (M.W.B., E.W.T., A.P.IJ.) and Division of Molecular Genetics, Leiden Institute of Chemistry, Leiden University, Leiden, the Netherlands (H.D., J.B.)

Adenosine A2B receptors are known as low-affinity receptors due to their modest-to-negligible affinity for adenosine and prototypic agonists. Despite numerous synthetic efforts, 5'-N-ethylcarboxamidoadenosine (NECA) still is the reference agonist, albeit nonselective for this receptor. In our search for higher affinity agonists, we developed decision schemes to select amino acids for mutation to the corresponding residues in the most homologous, higher affinity, human A2A receptor. One scheme exploited knowledge on sequence alignments and modeling data and yielded three residues, V11, L58, and F59, mutation of which did not affect agonist affinity. The second scheme combined knowledge on sequence alignments and mutation data and pointed to Ala12 and Asn273. Mutation of Ala12 to threonine did not affect the affinity for NECA, (R)-N6-(phenylisopropyl)adenosine (R-PIA), and 2Cl Ado. The affinity of the N273Y mutant for NECA and R-PIA and for the antagonists xanthine amine congener (XAC), ZM241385, and SCH58261 was also unaltered. However, this mutant had a slightly increased affinity for a 2-substituted adenosine derivative, CGS21680. This prompted us to investigate other 2-substituted adenosines, with selectivity and high affinity for A2A receptors. All four compounds tested had improved affinity for the N273Y receptor. Of these, 2-(1-hexynyl)adenosine had submicromolar affinity for the N273Y receptor, 0.18 ± 0.10 µM, with a 61-fold affinity gain over the wt receptor. In addition, the non-NECA analog (S)-PHP adenosine had an affinity of 1.7 ± 0.5 µM for the wt receptor. The high affinity of (S)-PHP adenosine for the wt receptor suggests that further modifications at the 2-position may yield agonists with even higher affinity for A2B receptors.


Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
Z.-G. Gao, A. Chen, D. Barak, S.-K. Kim, C. E. Muller, and K. A. Jacobson
Identification by Site-directed Mutagenesis of Residues Involved in Ligand Recognition and Activation of the Human A3 Adenosine Receptor
J. Biol. Chem., May 17, 2002; 277(21): 19056 - 19063.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
B. B. Fredholm, A. P. IJzerman, K. A. Jacobson, K.-N. Klotz, and J. Linden
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
Pharmacol. Rev., December 1, 2001; 53(4): 527 - 552.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics